The global nucleic acid therapeutics market revenue was around US$ 4.5 billion in 2022 and is estimated to reach US$ 12 billion by 2031, growing at a compound annual growth rate (CAGR) of 11.6% during the forecast period from 2023 to 2031.
Nucleic acid therapeutics include both Ribonucleic acid (RNA) and Deoxyribonucleic acid (DNA) therapeutics, which are further categorized into enzymes, antisense oligonucleotides, DNA aptamers, ribozymes, micro-RNA, RNA decoys, and short interfering RNA. They are made to target the contaminated genes without endangering healthy cells or tissues.
Market Driving Factors
Regulatory agencies such as the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have established clear guidelines and accelerated pathways for the approval of nucleic acid-based therapeutics. These regulatory frameworks have facilitated companies to finance the development of these therapies, boosting market growth.
Increasing collaborations and partnerships open up new prospects in the market. Collaboration between biotechnology firms, pharmaceutical companies, and academic institutions has become more prevalent in nucleic acid-based therapeutics. In addition, partnerships promote knowledge sharing, resource pooling, and technical advancements, leading to more immediate product development and commercialization.
The immediate advancements in molecular biology, genomics, and gene editing technologies have paved the way for the development of nucleic acid-based therapeutics. Additionally, techniques such as RNA interference (RNAi) and CRISPR-Cas9 gene editing have expanded the prospects for exact and targeted therapeutic interventions.
Nucleic acid therapeutics require extensive research, clinical trials, and regulatory procedures to develop and commercialize. As a result, large investments are needed for these operations, which can be a major obstacle for startups and smaller businesses, reducing their ability to compete in the market.
Regional Analysis
Asia-Pacific dominated the market in terms of substantial growth and is estimated to maintain its dominance. This can be attributed to the surge in government initiatives to facilitate awareness, the increase in medical tourism, the surge in research activities in the region, the availability of enormous untapped markets, a large population pool, and the growth in demand for quality healthcare in the region.
North America is expected to dominate the market in terms of the substantial share. This is owing to the increasing research on several nucleic acid-based therapies, the surging prevalence of genetic disorders and other chronic disorders, and increasing R&D investments in the region. Furthermore, the increasing prevalence of autoimmune diseases among the population increases the demand for nucleic acid-based therapies, which may boost the market growth. Moreover, the need for cutting-edge, efficient medications that stop cancer cells from spreading grows as the incidence of cancer rises. This increases the need for medications based on nucleic acids in the area. For instance, in June 2023, the Cancer Facts and Figures anticipate that the number of new cancer cases diagnosed in the nation in 2023 will be approximately 1.9 million.
Segmentation Insights
End User Insight
The hospitals & clinics segment dominates the market in terms of the highest revenue. This is due to the surge in the use of RNA-based therapeutics for the treatment of genetic disorders. Furthermore, rising understanding and advancements of RNA-based therapeutics, the increasing number of trends in personalized medicine, the surging prevalence of chronic diseases, and the growing research finances by private foundations, governments, and industry stakeholders. Thus, these elements are estimated to propel the market growth.
The academic and research institutes segment dominates the market in terms of growth rate. This is primarily due to the increasing research activities worldwide that have led to the development of novel strategies for new chemistries accompanied by an extended collection of nucleic acid agents. Moreover, key players increasingly concentrate on consumer convenience and high-quality industrial-scale services for academic research institutions globally.
Prominent Companies
Segmentation Outline
The global nucleic acid therapeutics market segmentation focuses on the Products, Application, End User, and Region.
By Products
By Application
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL NUCLEIC ACID THERAPEUTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: NUCLEIC ACID THERAPEUTICS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL NUCLEIC ACID THERAPEUTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS
5.1 OVERVIEW
5.2 ANTI-SENSE OLIGONUCLEOTIDES (ASOS) AND DNA APTAMERS
5.3 RNA INTERFERENCE [RNAI] AND SHORT INTERFERING RNAS [SIRNAS]
5.4 OTHERS
6 GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 MONOGENETIC DISORDERS
6.3 MULTI-GENETIC DISORDERS
7 GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY END USER
7.1 OVERVIEW
7.2 HOSPITALS AND CLINICS
7.3 ACADEMIC AND RESEARCH INSTITUTES
8 GLOBAL NUCLEIC ACID THERAPEUTICS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL NUCLEIC ACID THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 GENZYME SANOFI
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 AGILENT TECHNOLOGIES
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 BENITEC BIOPHARMA
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 COPERNICUS
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 QAIGEN NV
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 ARBUTUS BIOPHARMA
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 SARPETA THERAPEUTICS
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 PROTAGONIST THERAPEUTICS
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 MERCK KGAA
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 THERMO FISHER SCIENTIFIC
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 SILENCE THERAPEUTICS
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 NOVARTIS AG
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved